The findings are “extremely important for us, and helps us understand very well the pattern of how this drug behaves in these different populations, according to age and weight and so forth,” Supernus President and CEO Jack Khattar said in March. An FDA approval to commercialize the treatment — whose active ingredient, viloxazine hydrochloride, was marketed for years in Europe as an antidepressant — could make it “the first novel treatment to be introduced in the ADHD market in more than a decade,” Khattar said in a statement Monday.